Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Electron Microscopy Technique Boosts Development of Antibody-Based Vaccines

By LabMedica International staff writers
Posted on 22 Aug 2018
The novel use of an electron microscope imagining technique enabled vaccine developers to follow the design process of structure-based vaccines in real time.

Characterizing polyclonal antibody responses via currently available methods is inherently complex and difficult. More...
Mapping epitopes in an immune response is typically incomplete, which creates a barrier to fully understanding the humoral response to antigens and hinders rational vaccine design efforts.

To improve the antibody design process, investigators at the Scripps Research Institute (La Jolla, CA, USA) developed a method for characterizing polyclonal responses by using electron microscopy to produce negatively stained images of viruses bound to potential neutralizing antibodies. They applied this method to the immunization of rabbits with an HIV-1 envelope glycoprotein vaccine candidate, BG505 SOSIP.664.

The investigators reported in the August 7, 2018, online edition of the journal Immunity that they detected known epitopes within the polyclonal sera and revealed how antibody responses evolved during the prime-boosting strategy to ultimately result in a neutralizing antibody response. They uncovered previously unidentified epitopes, including an epitope proximal to one recognized by human broadly neutralizing antibodies as well as potentially distracting non-neutralizing epitopes.

High-resolution, three-dimensional images of the antibodies with their viral targets were obtained using cryo-electron microscopy (cryo-EM). Cryo-EM is an analytical technique that provides near-atomic structural resolution without requirements for crystallization or limits on molecular size and complexity imposed by the other techniques. Cryo-EM allows the observation of specimens that have not been stained or fixed in any way, showing them in their native environment while integrating multiple images to form a three-dimensional model of the sample.

"We can now watch antibody responses evolve almost in real time," said senior author Dr. Lars Hangartner, associate professor at the Scripps Research Institute. "This method has the potential to change the pace at which we can develop vaccines."

Related Links:
Scripps Research Institute


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Hematology Analyzer
Medonic M32B
New
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.